What the latest pain guidance means for people with arthritis

For most people living with chronic arthritis pain, the big takeaway is simple: opioids are not automatically off the table, but they usually are not the first place to start.

That is the message in the CDC’s current clinical guidance on opioid prescribing, which is built around a practical question many patients care about: not just “Does this lower pain?” but “Does this help me walk, sleep, work, cook, care for family, or get through the day more safely?” The CDC says non-opioid therapies are preferred for subacute and chronic pain when their expected benefits outweigh their risks, and that decisions about opioids should be individualized rather than driven by a rigid formula.

This matters because arthritis is not one condition. Osteoarthritis and inflammatory arthritis can both hurt, but they are not treated the same way. And in the United States, what sounds best on paper can still run into cost, insurance, travel, and scheduling barriers in real life.

Why this matters for millions of people

According to the CDC, osteoarthritis alone affects about 33 million U.S. adults. It is the most common type of arthritis and can cause pain, stiffness, swelling, and trouble with daily tasks. For many families, that means decisions about pain treatment are also decisions about mobility, work, caregiving, fall risk, and independence.

The challenge is that stronger pain medicine is not always better care. A treatment can lower pain temporarily while making dizziness, constipation, sedation, or falls worse. That is why current guidance puts so much emphasis on function and safety, not pain scores alone.

What current CDC guidance actually says about opioids

The CDC guidance is sometimes described as if it were a brand-new rule. It is not. It is the standing federal clinical framework that continues to shape care in 2026, and it stresses that recommendations are voluntary and should support, not replace, individualized care.

For chronic pain, the CDC says clinicians should first maximize non-drug approaches and non-opioid medicines that fit the person’s condition. If opioids are considered, the expected benefit should include both pain relief and improvement in function. The CDC also advises setting realistic goals before starting them, using the lowest effective dose, favoring immediate-release products when starting, and following up within one to four weeks after initiation or dose escalation.

Just as important, the CDC warns against abrupt discontinuation in people who are already taking long-term opioids. The goal is careful, person-centered prescribing, not a blanket yes or no.

Why arthritis treatment depends on the type

Osteoarthritis is usually a wear-and-tear and joint-tissue disease. The CDC and the American College of Rheumatology and Arthritis Foundation both point patients first toward exercise therapy, weight management when relevant, self-management programs, and joint-protecting strategies. In plain language, that often means a plan built around movement, strengthening, pacing, and pain relief that lets you keep using the joint safely.

Inflammatory arthritis, including rheumatoid arthritis, is different. Here, pain is often being driven by immune-system inflammation. The 2021 American College of Rheumatology guideline for rheumatoid arthritis focuses on disease-modifying treatment, often starting with medicines such as methotrexate or other DMARDs, then adjusting toward low disease activity or remission. In other words, the best pain strategy is often better control of the disease itself, not simply adding stronger pain medicine on top.

That distinction is easy to miss but it changes everything. If someone with osteoarthritis is told to move more and try topical anti-inflammatory treatment, that can be evidence-based care. If someone with active inflammatory arthritis is only cycling through pain medicines while joint inflammation stays uncontrolled, that can mean the main problem is not being addressed.

Which non-opioid options have the best evidence

For osteoarthritis, the strongest evidence is not always for a pill. The American College of Rheumatology guideline strongly recommends exercise for knee and hip osteoarthritis, weight loss for people with knee or hip osteoarthritis who are overweight, and self-management approaches. It also strongly recommends topical NSAIDs for knee osteoarthritis and oral NSAIDs for hand, hip, and knee osteoarthritis when they are safe for the individual patient.

A large BMJ network meta-analysis of drug treatment for knee and hip osteoarthritis found that topical diclofenac and oral NSAIDs can help many people, with topical treatment offering the advantage of less whole-body exposure. But reviews like this have limits. They combine trials with different designs, often short follow-up, and they mostly reflect knee and hip osteoarthritis rather than every painful joint. That means the results are useful, but they are not a perfect ranking for every person sitting in an exam room.

Injections also need plain-language context. Corticosteroid injections may help some people for short-term relief, especially during a bad flare in one joint, but they are not a reset button and they do not rebuild cartilage. Evidence is much weaker or more inconsistent for many supplements, devices, and newer procedures that patients may hear about online or in advertising.

For inflammatory arthritis, the evidence hierarchy looks different. The strongest support is for disease-modifying therapy that brings inflammation down. Pain medicines can still have a role, especially during a flare or while a disease-targeting medicine is starting to work, but long-term opioid escalation is not the core treatment pathway.

When opioids may still come up

There are situations where opioids may still be discussed for arthritis pain. Examples include severe pain with major functional impairment, failure or intolerance of safer options, or a short-term bridge in selected circumstances. But “may be considered” is not the same thing as “should be routine.”

If opioids enter the conversation, careful prescribing should include a discussion of what success would actually look like. Is the goal getting out of bed independently? Sleeping through the night? Managing a temporary crisis while another treatment takes effect? The CDC recommends reviewing overdose risk, other sedating medications, and the patient’s prescription history, and considering naloxone when risk is higher.

Patients should also know the common tradeoffs. Opioids can cause sedation, slowed breathing, dizziness, constipation, and impaired thinking. The FDA has warned that combining them with benzodiazepines, alcohol, or other central nervous system depressants can sharply raise the risk of dangerous oversedation and overdose. In older adults, that can also mean a higher fall risk.

The safety questions matter with non-opioids too

“Non-opioid” does not mean “without risk.” NSAIDs can be very helpful, but the FDA warns they can raise the risk of heart attack or stroke and can also cause stomach bleeding. They can be a poor fit for some people with kidney disease, ulcer history, bleeding risk, heart disease, or advanced age. That is why it is worth asking whether a topical NSAID, a lower dose, a shorter course, or a different option makes more sense for you.

Steroids also deserve caution. Whether the plan involves oral steroids or joint injections, patients should ask how long the benefit is expected to last, how often the treatment can reasonably be repeated, and what side effects matter given diabetes, bone health, infection risk, and the rest of their medication list.

Cost, insurance, and access often shape the real treatment plan

In everyday care, the best-supported option is not always the easiest to get. Physical therapy may require a referral, time off work, transportation, childcare, copays, and appointment slots that are hard to find. For people in rural areas, even one extra trip a week can be a barrier.

CMS says Medicare covers outpatient therapy when it is medically necessary, but there are still billing thresholds and documentation rules. For calendar year 2026, claims above $2,480 for physical therapy and speech-language pathology combined, and above $2,480 for occupational therapy, require added documentation using the KX modifier. A targeted medical review threshold of $3,000 also remains in place. Those rules do not mean therapy stops at a fixed dollar amount, but they can add paperwork and friction.

Access problems are not just theoretical. In March 2026, the American Physical Therapy Association said prior authorization and utilization review continue to delay medically necessary therapy and disrupt continuity of care. For arthritis patients, that can mean the conservative care guidelines recommend is exactly the care that is hardest to start or continue.

Drug coverage can be just as uneven. Coverage for injections, specialty medicines, and biologics varies widely by plan. Medicare has new protections that matter, including a 2026 annual out-of-pocket cap of $2,100 for covered Part D drugs, but that does not mean every arthritis medicine will be equally affordable or equally easy to access. As Associated Press reporting has noted in coverage of Medicare drug negotiations, the price a patient actually pays at the pharmacy counter still depends heavily on plan design and how much they have already spent during the year.

Questions to bring to your next visit

What kind of arthritis do I most likely have, and how does that change treatment?
What treatment is most likely to improve my function, not just lower my pain score?
If I try an NSAID, what do my kidney, stomach, bleeding, or heart risks look like?
If steroids or injections are part of the plan, what benefit is realistic and what are the downsides?
If opioids are being considered, what are the goals, how soon will we reassess, and how will we watch for sedation, constipation, or interactions?
Do I need a referral or prior authorization for physical therapy, injections, or advanced arthritis medicines?
What will my insurance cover, and what lower-cost alternatives are reasonable if coverage is poor?

What this means for readers

Most people with chronic arthritis pain should expect non-opioid strategies to come before opioids. But the best plan depends on the type of arthritis, the person’s other health conditions, and what improves real life function. For osteoarthritis, movement, physical therapy, weight management when relevant, and topical anti-inflammatory treatment often matter as much as or more than stronger pain medicine. For inflammatory arthritis, bringing the disease under control is usually the most effective pain strategy.

The bottom line is not “never opioids” and it is not “just live with it.” It is that good arthritis care should match the right treatment to the right kind of pain, with a clear-eyed view of safety, function, cost, and access.

Sources

This article is for general informational purposes only and is not medical advice. Research findings can be early, limited, or subject to change as new evidence emerges. For personal guidance, diagnosis, or treatment, consult a licensed clinician. For current outbreak or public health guidance, follow your local health department, the CDC, or another relevant public health authority.